Parsippany Chapter Upcoming Events Join PCCI

 

Third Eye Diagnostics Inc.

A non-invasive medical device company

Presenter: Terry Fuller PhD, CEO

 

Monday, December 11, 2017

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

About

 

Third Eye Diagnostics Inc. has developed the CerePress,™ a non-invasive medical device to measure intracranial pressure (ICP) which is critical for the management of hydrocephalus and for assessing the onset and extent of traumatic brain injuries (TBI). Elevated ICP inhibits blood flow to the brain, placing patients at risk for brain damage and death. Early detection of patients suffering from neurological deterioration due to elevated ICP results in improved patient outcome and reduced hospital stay. However, current ICP monitoring is invasive, performed by drilling a hole in the skull and inserting a pressure transducer into the cranium. As a result, ICP monitoring is only performed on TBI patients who are already critically ill. There are no FDA cleared devices to measure ICP.

 

In response, Third Eye has developed the CerePress. The system consists of a handheld device and a single- use, patented, disposable optical cap that will result in a trailing revenue stream. The CerePress has been developed to address an estimated $40 billion unmet need for non-invasive ICP measurement. It provides an indispensable “spot check" of ICP in an easy-to-use, accurate and rapid (under 30-second) package. It can be used with minimal training in the ER, ICU, surgical suite, in the battlefield, in sporting and medical transport settings, and potentially in the home.

 

Third Eye has 4 granted patents and has one pending patent application. The technology has been clinically validated in 2 published studies, and further validated and substantially funded by the National Science Foundation (NSF). Third Eye Diagnostics forecasts revenue in excess of $40MM within 4 years of product launch. 

 

 

3 Major Issues

 

REIMBURSEMENT QUESTION

1. What are the hurdles in obtaining a reimbursement code for ICP monitoring by:

a. Health professionals
i. Contributing to a diagnosis
ii. Following changes in condition and contributing to treatment

b. Patient or family member in the home:
i. Detecting condition change or ruling out perceived symptom within physician
designated norms

Example (analogy to a thermometer)
If ICP is below 10 mmHg, (below physician designated norm): No action required
If ICP is between 10 and 18 mmHg (High normal for that patient): Call physician
If ICP is greater than 18, call 911.

 

MARKETING QUESTION

2. In management of a hydrocephalus shunt patient:
a. What is the average or typical cost to manage a patient having a suspected shunt failure?
b. How many ER visits does such a patient make per year? What percentage of the visits are
shunt failures, i.e., false positive visits/discharge for ER?
c. What percentage of the patients sent for invasive/surgical ICP procedures are found not to
have an elevated ICP? Are such records considered reliable, i.e., will surgeons admit that
there was no elevation of ICP?

 

REGULATORY/REIMBURSEMENT QUESTION

3. Durable Medical Device designation
a. Do chronic patient monitoring devices qualify for coverage as a DME or Service?
b. How does the clinical indication factor into obtaining DMR coverage?
c. Does the cost of a device impact coverage? An associated disposable?
d. How do digital health or telemedicine devices factor in?

 

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Terry Fuller PhD, CEO will deliver Greene Street's "Elevator" Pitch to the Group

8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests

 

 


Reservation

 

Reserve your spot for this special event online now though PayPal.

Please note: You do not need a PayPal account to reserve your spot, most credit cards are accepted.

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

Third Eye Diagnostics Webcast - 12/11/2017

00:00:00  CEO Terry Fuller
00:23:00  Panel assembles
00:23:40  Panel introductions (Gary Gilberty, Mike Daley, with moderator Jordan Warshafsky)

01:03:10  Mike Daley's slides on reimbursement

01:20:00  (approximately)  Audience comments

 

Contact Info:

 

 

Our Sponsors

EisnerAmperGlaxoSmithKlineKEH Insurance Agency
New Jersey Institute of Technology
Science CenterWhite and Williams

 

<Top of the page>

 

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc